5-Amino-1MQ
UnregulatedAlso known as: 5-amino-1-methylquinolinium, NNMT inhibitor
Metabolic & Weight ManagementLast reviewed: April 28, 2026
A small molecule inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme that regulates fat cell metabolism and NAD+ availability. While technically a small molecule rather than a peptide, it is commonly grouped with peptide therapies in the metabolic health space due to its mechanism and delivery method.
Mechanism of Action
Inhibits NNMT, which normally converts NAD+ precursors into methylnicotinamide — a metabolic dead end. By blocking NNMT, 5-Amino-1MQ increases NAD+ availability in fat cells, activating SIRT1 and promoting fat oxidation. Reduces fat cell size and inhibits new fat cell formation (adipogenesis).
Common Uses
- Fat loss and body composition
- Metabolic health improvement
- Obesity treatment (investigational)
- NAD+ pathway optimization
Known Risks
- Very limited human clinical data
- Long-term safety unknown
- Optimal dosing not established
- Potential off-target effects of NNMT inhibition not fully characterized
- Often sourced from gray-market vendors with variable quality
Regulatory Status
Not FDA-approved and not on any compounding list. Available as a research chemical. Growing interest in the metabolic health community but human clinical trial data is extremely limited. Not a peptide in the strict sense — a small molecule — but commonly discussed alongside peptide therapies.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Oral capsule
Typical Dose
50–100 mg
Frequency
Once daily
Cycle Length
8–12 weeks
Oral bioavailability is reasonable for this small molecule. Often stacked with NAD+ precursors (NMN/NR) since both target the NAD+ pathway from different angles. Take with food.
Related Compounds
Research References
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.